Sg3 Management, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $1.75 Million - $2.96 Million	-50,000 Reduced 50.0%	50,000 $2.26 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $3.55 Million - $5.41 Million	100,000 New	100,000 $5.08 Million
Q4 2021 Feb 15, 2022	SELL	$30.74 - $49.16 $8.17 Million - $13.1 Million	-265,700 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $6.14 Million - $13.7 Million	195,700 Added 279.57%	265,700 $8.76 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $2.23 Million - $3.54 Million	54,500 Added 351.61%	70,000 $4.42 Million
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $632,400 - $889,545	15,500 New	15,500 $665,000
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $461,850 - $858,000	-15,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $388,350 - $504,750	15,000 New	15,000 $453,000

309

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.38B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.